34
Active Trials
19
Phase 1
12
Phase 2
8
Phase 3
5
Therapeutic Areas
Portfolio Concentration: 165% of active trials in Oncology
Oncology
56 active / 140 total
Solid Tumor (Advanced)
9 active
32 total since 2015
Non-Hodgkin Lymphoma
6 active
3 Ph3
21 total since 2015
NSCLC
6 active
2 Ph3
14 total since 2015
CLL
4 active
1 Ph3
8 total since 2015
Esophageal Cancer
3 active
12 total since 2015
Breast Cancer
3 active
4 total since 2015
Bladder Cancer
3 active
1 Ph3
4 total since 2015
SCLC
2 active
5 total since 2015
Gastric Cancer
2 active
4 total since 2015
Ovarian Cancer
2 active
1 Ph3
3 total since 2015
HER2- Breast Cancer
2 active
3 total since 2015
Lung Cancer (General)
2 active
3 total since 2015
Colorectal Cancer
2 active
3 total since 2015
Prostate Cancer
1 active
2 total since 2015
Triple Negative Breast Cancer
1 active
2 total since 2015
Hematologic Malignancies
1 active
2 total since 2015
Head and Neck Cancer
1 active
2 total since 2015
Endometrial Cancer
1 active
1 total since 2015
AML
1 active
1 total since 2015
MDS
1 active
1 total since 2015
Pancreatic Cancer
1 active
1 total since 2015
Renal Cell Carcinoma
1 active
1 total since 2015
Melanoma
1 active
1 total since 2015
Hepatocellular Carcinoma
0 active
6 total since 2015
Hodgkin Lymphoma
0 active
3 total since 2015
Cervical Cancer
0 active
1 total since 2015
Immunology
5 active / 9 total
Cardiovascular
2 active / 7 total
Urology
1 active / 1 total
Infectious Disease
0 active / 3 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)